{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T23:39:55Z","timestamp":1785886795281,"version":"3.56.0"},"reference-count":40,"publisher":"BMJ","issue":"2","license":[{"start":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T00:00:00Z","timestamp":1707350400000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2024,1,11]]},"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Obesity is associated with lower treatment response in patients with rheumatoid arthritis (RA). In patients with obesity, abatacept was suggested as a preferable option to tumour necrosis factor-alpha inhibitors. We aimed to assess the comparative effectiveness of etanercept, infliximab and abatacept, compared with adalimumab, in patients with RA with obesity. Secondarily, we also investigated this in patients with overweight and normal weight for completeness.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Observational cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>Swiss Clinical Quality Management in Rheumatic Diseases (SCQM) registry (1997\u20132019).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>Adult patients with RA from the SCQM registry who received etanercept, infliximab, abatacept or adalimumab as their first biological or targeted synthetic disease-modifying antirheumatic drug were classified based on their body mass index (BMI) at the start of that treatment in three cohorts: obese, overweight, normal weight. They were followed for a maximum of 1 year.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>The study exposure of interest was the patients\u2019 first biological, particularly: etanercept, infliximab and abatacept, compared with adalimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Primary and secondary outcome measures<\/jats:title>\n                    <jats:p>The primary study outcome was remission within 12\u2009months, defined as 28-joint Disease Activity Score (DAS28) &lt;2.6. Missingness was addressed using confounder-adjusted response rate with attrition correction. Logistic regression was used to compare the effectiveness of etanercept, infliximab and abatacept versus adalimumab. Each BMI cohort was addressed and analysed separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study included 443 obese, 829 overweight and 1243 normal weight patients with RA. There were no statistically significant differences in the odds of DAS28-remission at \u226412\u2009months for etanercept, infliximab and abatacept, compared with adalimumab, in any of the BMI cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>No differences in DAS28-remission were found between the study drugs and adalimumab as first biologic in patients with RA, independently of the BMI cohort. We did not find evidence that treatment with abatacept increased the likelihood of remission compared with adalimumab among obese patients with RA.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2023-074864","type":"journal-article","created":{"date-parts":[[2024,2,8]],"date-time":"2024-02-08T21:40:35Z","timestamp":1707428435000},"page":"e074864","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Comparative effectiveness of biologics in patients with rheumatoid arthritis stratified by body mass index: a cohort study in a Swiss registry"],"prefix":"10.1136","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5911-2037","authenticated-orcid":false,"given":"Enriqueta","family":"Vallejo-Yag\u00fce","sequence":"first","affiliation":[{"name":"Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland"},{"name":"Institute of Primary Health Care (BIHAM), University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theresa","family":"Burkard","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1210-4347","authenticated-orcid":false,"given":"Axel","family":"Finckh","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Geneva University Hospitals, Geneve, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-8530","authenticated-orcid":false,"given":"Andrea Michelle","family":"Burden","sequence":"additional","affiliation":[{"name":"Pharmacoepidemiology Group, Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,2,8]]},"reference":[{"key":"2025121604553213000_14.2.e074864.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2018.1"},{"key":"2025121604553213000_14.2.e074864.2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41413-018-0016-9","article-title":"Rheumatoid arthritis: pathological mechanisms and modern pharmacologic therapies","volume":"6","author":"Guo","year":"2018","journal-title":"Bone Res"},{"key":"2025121604553213000_14.2.e074864.3","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2025121604553213000_14.2.e074864.4","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-216656"},{"key":"2025121604553213000_14.2.e074864.5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056352","article-title":"Interruptions of biological and targeted synthetic disease-modifying antirheumatic drugs in rheumatoid arthritis: a descriptive cohort study assessing trends in patient characteristics in Switzerland","volume":"12","author":"Burkard","year":"2022","journal-title":"BMJ Open"},{"key":"2025121604553213000_14.2.e074864.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.190535"},{"key":"2025121604553213000_14.2.e074864.7","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40744-017-0078-y","article-title":"Discontinuation of Biologic Therapy in Rheumatoid Arthritis: Analysis from the Corrona RA Registry","volume":"4","author":"Strand","year":"2017","journal-title":"Rheumatol Ther"},{"key":"2025121604553213000_14.2.e074864.8","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s13075-019-1917-8","article-title":"Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata\u00ae clinical database and registry","volume":"21","author":"Choquette","year":"2019","journal-title":"Arthritis Res Ther"},{"key":"2025121604553213000_14.2.e074864.9","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/acr.22932","article-title":"Impact of obesity on remission and disease activity in rheumatoid arthritis: A systematic review and Meta\u2010Analysis","volume":"69","author":"Liu","year":"2017","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025121604553213000_14.2.e074864.10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0195123","article-title":"Obesity and response to anti-tumor necrosis factor-\u03b1 agents in patients with select immune-mediated inflammatory diseases: A systematic review and meta-analysis","volume":"13","author":"Singh","year":"2018","journal-title":"PLoS One"},{"key":"2025121604553213000_14.2.e074864.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-205094"},{"key":"2025121604553213000_14.2.e074864.12","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1194-8","article-title":"Impact of body weight on the achievement of minimal disease activity in patients with rheumatic diseases: a systematic review and meta-analysis","volume":"18","author":"Lupoli","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025121604553213000_14.2.e074864.13","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10067-020-04963-2","article-title":"Obesity and its role in the management of rheumatoid and psoriatic arthritis","volume":"39","author":"Moroni","year":"2020","journal-title":"Clin Rheumatol"},{"key":"2025121604553213000_14.2.e074864.14","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.jbspin.2018.03.007","article-title":"Impact of obesity on the efficacy of different biologic agents in inflammatory diseases: A systematic review and meta-analysis","volume":"86","author":"Shan","year":"2019","journal-title":"Joint Bone Spine"},{"key":"2025121604553213000_14.2.e074864.15","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-016-1043-9","article-title":"Body mass index distribution in rheumatoid arthritis: a collaborative analysis from three large German rheumatoid arthritis databases","volume":"18","author":"Albrecht","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"2025121604553213000_14.2.e074864.16","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10143194","article-title":"Comparison of Psoriatic Arthritis and Rheumatoid Arthritis Patients across Body Mass Index Categories in Switzerland","volume":"10","author":"Vallejo-Yag\u00fce","year":"2021","journal-title":"J Clin Med"},{"key":"2025121604553213000_14.2.e074864.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.07.001"},{"key":"2025121604553213000_14.2.e074864.18","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40262-018-0676-z","article-title":"Clinical Pharmacokinetic and Pharmacodynamic Considerations in the Treatment of Ulcerative Colitis","volume":"58","author":"Berends","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025121604553213000_14.2.e074864.19","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/jcph.1732","article-title":"Increased Induction Infliximab Clearance Predicts Early Antidrug Antibody Detection","volume":"61","author":"Eser","year":"2021","journal-title":"J Clin Pharmacol"},{"key":"2025121604553213000_14.2.e074864.20","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1111\/jan.13511","article-title":"Impact of weight stigma on physiological and psychological health outcomes for overweight and obese adults: A systematic review","volume":"74","author":"Wu","year":"2018","journal-title":"J Adv Nurs"},{"key":"2025121604553213000_14.2.e074864.21","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1007\/s10067-017-3788-1","article-title":"Body mass index and clinical response to intravenous or subcutaneous abatacept in patients with rheumatoid arthritis","volume":"36","author":"D\u2019Agostino","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025121604553213000_14.2.e074864.22","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/eci.12691","article-title":"Body mass index and response to abatacept in rheumatoid arthritis","volume":"46","author":"Gardette","year":"2016","journal-title":"Eur J Clin Invest"},{"key":"2025121604553213000_14.2.e074864.23","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1007\/s10067-016-3505-5","article-title":"Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the \"pan-European registry collaboration for abatacept (PANABA)","volume":"36","author":"Iannone","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2025121604553213000_14.2.e074864.24","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.jbspin.2016.10.011","article-title":"The effect of body mass index on clinical response to abatacept as a first-line biologic for rheumatoid arthritis: 6-month results from the 2-year, observational, prospective ACTION study","volume":"84","author":"Mariette","year":"2017","journal-title":"Joint Bone Spine"},{"key":"2025121604553213000_14.2.e074864.25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2011-150573"},{"key":"2025121604553213000_14.2.e074864.26","unstructured":"SCQM Foundation, Research, Available: https:\/\/www.scqm.ch\/en\/research\/overview\/"},{"key":"2025121604553213000_14.2.e074864.27","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221307"},{"key":"2025121604553213000_14.2.e074864.28","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-221477"},{"key":"2025121604553213000_14.2.e074864.29","unstructured":"R Core Team . R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2020. Available: https:\/\/www.r-project.org\/"},{"key":"2025121604553213000_14.2.e074864.30","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217209"},{"key":"2025121604553213000_14.2.e074864.31","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2020-001174","article-title":"Comparative effectiveness of antitumour necrosis factor agents, biologics with an alternative mode of action and tofacitinib in an observational cohort of patients with rheumatoid arthritis in Switzerland","volume":"6","author":"Finckh","year":"2020","journal-title":"RMD Open"},{"key":"2025121604553213000_14.2.e074864.32","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2022-222586"},{"key":"2025121604553213000_14.2.e074864.33","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1111\/bcp.12709","article-title":"The comparative effectiveness of biologics among older adults and disabled rheumatoid arthritis patients in the Medicare population","volume":"80","author":"Yun","year":"2015","journal-title":"Br J Clin Pharmacol"},{"key":"2025121604553213000_14.2.e074864.34","doi-asserted-by":"publisher","DOI":"10.1002\/art.37711"},{"key":"2025121604553213000_14.2.e074864.35","doi-asserted-by":"crossref","DOI":"10.1111\/obr.13393","article-title":"Sex differences in regional adipose tissue depots pose different threats for the development of Type 2 diabetes in males and females","volume":"23","author":"Delaney","year":"2022","journal-title":"Obes Rev"},{"key":"2025121604553213000_14.2.e074864.36","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.molmet.2018.04.003","article-title":"Sex differences in obesity, lipid metabolism, and inflammation-A role for the sex chromosomes?","volume":"15","author":"Zore","year":"2018","journal-title":"Mol Metab"},{"key":"2025121604553213000_14.2.e074864.37","doi-asserted-by":"crossref","DOI":"10.1007\/s11892-018-1031-3","article-title":"Gender and Sex Differences in Adipose Tissue","volume":"18","author":"Chang","year":"2018","journal-title":"Curr Diab Rep"},{"key":"2025121604553213000_14.2.e074864.38","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.126532"},{"key":"2025121604553213000_14.2.e074864.39","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-204573"},{"key":"2025121604553213000_14.2.e074864.40","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2021-220202"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2023-074864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T12:55:40Z","timestamp":1765889740000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2023-074864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2]]},"references-count":40,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,2,8]]},"published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1136\/bmjopen-2023-074864"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2023-074864","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2]]}}}